What CS585 is
CS585 is Cereno Scientific’s preclinical drug candidate being developed for rare thrombotic disorders, where abnormal blood clot formation poses serious long-term risks and current treatment options are limited by bleeding concerns.
CS585 is a highly potent, selective prostacyclin (IP) receptor agonist, designed to reduce platelet activation and clot formation without increasing bleeding risk. This is a key limitation of many existing anti-thrombotic therapies.
The program is being advanced through a research collaboration with the University of Michigan, a leading center for cardiovascular and thrombosis research, and is currently undergoing preclinical evaluation.
Why a new approach to thrombosis is needed
Many current anti-thrombotic treatments reduce clotting effectively but at the cost of increased bleeding risk, particularly during long-term use. This trade-off is especially problematic in rare thrombotic conditions, where safer chronic treatment options are needed.
CS585 aims to address this unmet need through selective modulation of platelet activity, rather than broad suppression of coagulation.
Scientific rationale – selective activation of the IP receptor
CS585 works by selectively activating the prostacyclin (IP) receptor, a key pathway involved in regulating platelet function and vascular health.
By targeting this pathway, CS585 is designed to:
- Inhibit platelet activation
- Reduce clot formation
- Preserve normal clotting function
This selective mechanism differentiates CS585 from traditional anticoagulant approaches.
Preclinical development
CS585 is currently in preclinical development. Preclinical studies to date support its potential as a well-tolerated, oral anti-thrombotic therapy.
Detailed scientific data have been published in peer-reviewed journals and presented at international scientific conferences.
Research collaboration
CS585 originates from research conducted at the University of Michigan.
Cereno holds exclusive rights to further develop and commercialize CS585 and continues to advance the program through this collaboration.
Section title
Next steps
Ongoing preclinical work is focused on advancing CS585 toward clinical readiness, subject to further evaluation and regulatory considerations.